Previous clinical trials of agents developed to treat Ebola have shown monoclonal neutralizing antibodies can reduce viremia, attenuate virulence, substantially improve clinical symptoms and reduce the mortality of those infected.
未经许可，严禁转发。QQ交流群：688169419